Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00732563 · ClinicalTrials.gov registry record · NA
Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery
A NA study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT00732563 is a NA study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 100 participants.
The verdict
NCT00732563, a NA study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
RATIONALE: Diagnostic procedures using fludeoxyglucose F 18 and a surgical probe may help find lymph node metastases in patients with early-stage non-small cell lung cancer. PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 works in detecting lymph node metastasis in patients with stage I or stage II non-small cell lung cancer that can be removed by surgery.
Interventions
- PROCEDURE therapeutic conventional surgery
- PROCEDURE quality-of-life assessment
- DRUG chemotherapy
- PROCEDURE neoadjuvant therapy
- PROCEDURE lymphadenectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-07-16 |
| Est. Completion | 2017-07-26 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00732563
The ClinicalTrials.gov registry entry for NCT00732563 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which therapeutic conventional surgery is the first listed.
NCT00732563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00732563 about?
NCT00732563 is a clinical study titled "Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery". RATIONALE: Diagnostic procedures using fludeoxyglucose F 18 and a surgical probe may help find lymph node metastases in patients with early-stage non-small cell lung cancer. PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 works in detecting lymph node metastasis in patients w...
What is the current status of trial NCT00732563?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2008-07-16. Estimated completion is 2017-07-26.
What interventions are being tested in trial NCT00732563?
The interventions under investigation include: therapeutic conventional surgery (PROCEDURE), quality-of-life assessment (PROCEDURE), chemotherapy (DRUG), neoadjuvant therapy (PROCEDURE), lymphadenectomy (PROCEDURE).
Who is sponsoring clinical trial NCT00732563?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.